Other evidence of the regulatory functions of FGD5-AS1 came from studies of cancers such as colorectal cancer (Li et al., 2019), non-small lung cancer (Fan et al., 2020; Fu et al., 2020), gastric cancer (Gao et al., 2020a), melanoma (Gao et al., 2020b), oral cancer (Liu et al., 2020), glioblastoma (Su et al., 2020), glioma (Lin et al., 2020; Zhao et al., 2020), renal cell carcinoma (Yang et al., 2020), and hepatocellular carcinoma (Zhang and Lou, 2020). Here, FGD5 is linked to hepatocellular carcinoma.